#United States #Princeton #Made Scientific #Columbia University #NOVAKnee

Made Scientific Partners with Columbia University for NOVAKnee

In a groundbreaking development in orthopedic care, Made Scientific, Inc. has been selected as the manufacturer for the NOVAKnee program. This initiative is led by Columbia University’s School of Engineering and Vagelos College of Physicians and Surgeons under the auspices of the Advanced Research Projects Agency for Health (ARPA-H). As the first-ever living biologic total knee replacement, NOVAKnee represents a paradigm shift from traditional metal and plastic implants.

A New Era in Joint Replacement

The NOVAKnee program seeks to innovate knee replacement by introducing a biologic alternative that leverages a biodegradable scaffold populated with bone and cartilage progenitor cells. This living solution promises not only to restore joint function but also to foster biological tissue regeneration, moving away from the reliance on mechanical substitutes.

“Replacing traditional implants with a living, cell-based product is a significant leap in orthopedic care,” remarked Syed T. Husain, the Chairman and CEO of Made Scientific. This collaboration highlights the company's commitment to advancing medical technologies by ensuring precise manufacturing processes that meet rigorous FDA standards.

Collaborating for Clinical Advancement

Made Scientific's role in the NOVAKnee program extends to providing technology transfer, analytical and process development, alongside Good Manufacturing Practices (GMP) clinical manufacturing services. The implants will be used in a Phase 1 clinical trial in the U.S., expected to kick off in 2028. This will be a crucial step in establishing the viability and efficacy of the NOVAKnee solutions for real-world patients.

Dr. Clark Hung, Vice Chair and Professor of Biomedical Engineering at Columbia University, reiterated the importance of collaborating with a manufacturing partner that possesses deep expertise in cell therapy. He expressed optimism about pushing the NOVAKnee-L and NOVAKnee-T products forward towards their clinical trial stage.

Funding for Innovation

The collaboration is part of ARPA-H's NITRO initiative, which funds the NOVAJoint program at Columbia University to fast-track next-gen biologic solutions for joint replacement. This support underscores both organizations' commitment to integrating academic innovation with clinical development, providing cutting-edge solutions to medical challenges.

In its mission to defy limits and deliver results, Made Scientific's partnership with Columbia marks a significant step forward in the clinical application of regenerative medicine. Their expertise will facilitate the transition of these next-generation therapies from research environments to patients in need, showcasing their pivotal role in the landscape of health care innovation.

About Made Scientific

Headquartered in Princeton, New Jersey, Made Scientific specializes in the development, manufacturing, and release of both autologous and allogeneic cell therapy products tailored for clinical and commercial distribution. Operated as a clinical- and commercial-stage Contract Development and Manufacturing Organization (CDMO), they combine specialized services with robust technical expertise, positioning themselves as leaders in the field of cell therapies. With support from long-term backer GC Corporation, Made Scientific aims to deliver reliable and scalable solutions while driving groundbreaking advancements in therapeutic innovation.

For more information about their services and initiatives, visit Made Scientific’s official website.